Clinical Trials Directory

Trials / Completed

CompletedNCT00949546

Treatment of Hidradenitis Suppurativa Using Etanercept

Treatment of Hidradenitis Suppirativa With Etanercept Injection

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Penn State University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.

Conditions

Interventions

TypeNameDescription
DRUGetanerceptetanercept 50 mg sc twice weekly

Timeline

Start date
2005-04-01
Primary completion
2008-01-01
Completion
2008-01-01
First posted
2009-07-30
Last updated
2017-11-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00949546. Inclusion in this directory is not an endorsement.